Feel free to click on the bolded blue text within the article; it grants you complimentary access to the latest research and development updates on the drugs discussed. Recently, Daiichi Sankyo's investigational drug, Ifinatamab Deruxtecan (B7-H3 ADC), has successfully administered the first dose to a participant in a Phase III clinical trial (IDeate-Esophageal01) in China. This trial is specifically aimed at second-line treatment for advanced or metastatic esophageal squamous cell carcinoma. This innovative drug is on track to become the first antibody-drug conjugate (ADC) targeting B7-H3, developed using the cutting-edge DXd ADC technology platform. The progress of this study not only highlights Daiichi Sankyo's robust research and development capabilities but also emphasizes its dedication to the Chinese market. B7-H3 is notably overexpressed in a variety of cancers, with a particularly high prevalence in esophageal squamous cell carcinoma. This makes Ifinatamab Deruxtecan a highly promising new treatment avenue for patients. The research team is committed to pushing the study forward, and its successful development could significantly expand the potential applications of antibody-drug conjugate technology in cancer therapy. It's important to note that this article serves solely as a platform for information exchange and does not endorse any specific treatment plan. For personalized medical advice, please consult a reputable medical institution.